Prospecto: information for the user
Galvus 50mg tablets
vildagliptina
Read this prospect carefully before starting to take this medicine, as it contains important information for you.
1.What is Galvus and for what it is used
2.What you need to know before starting to take Galvus
3.How to take Galvus
4.Possible adverse effects
5.Storage of Galvus
6.Contents of the package and additional information
The active ingredient of Galvus, vildagliptin, belongs to a group of medications called «oral antidiabetics».
Galvus is used to treat adult patients with type 2 diabetes when the diabetes cannot be controlled solely by diet and exercise. It helps to control blood sugar levels. Your doctor will prescribe Galvus alone or in combination with other antidiabetic medications you are already taking if these are not effective enough to control diabetes.
Type 2 diabetes appears if the body does not produce enough insulin or if the insulin produced does not function properly. It can also appear if the body produces too much glucagon.
Insulin is a substance that helps to reduce blood sugar levels, especially after meals. Glucagon is a substance that promotes sugar production by the liver and causes blood sugar levels to rise. Both substances are produced in the pancreas.
How Galvus works
Galvus stimulates the pancreas to produce more insulin and less glucagon. This helps to control blood sugar levels. This medication has been shown to reduce blood sugar levels, which will help to prevent complications of your diabetes. Although you start taking this medication for your diabetes, it is essential that you continue with the diet and/or exercise that have been recommended.
Warnings and precautions
Consult your doctor, pharmacist, or nurse before starting to take Galvus
If you have previously taken vildagliptin but had to stop taking it due to liver disease, do not take this medication.
Skin lesions are common complications of diabetes. Follow your doctor's or nurse's recommendations for skin and foot care, paying special attention to the appearance of blisters or ulcers while taking Galvus. If this occurs, you should consult your doctor as soon as possible.
Liver function tests should be performed before starting treatment with Galvus, at three-month intervals during the first year, and periodically thereafter. This is done to detect as soon as possible any signs indicating an increase in liver enzymes (transaminases).
Children and adolescents
The administration of Galvus is not recommended in children and adolescents under 18years.
Use of Galvus with other medications
Inform your doctor or pharmacist if you are using, have used recently, or may need to use any other medication.
Your doctor may change your Galvus dose if you are taking other medications such as:
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, or think you may be pregnant, consult your doctor or pharmacist before using this medication.
You should not use Galvus during pregnancy. It is unknown whether Galvus passes into breast milk. Do not take Galvus if you are breastfeeding or plan to breastfeed.
Driving and operating machinery
If you feel dizzy while taking Galvus, do not drive or operate tools or machinery.
Galvus contains lactose
Galvus contains lactose (milk sugar). If your doctor has told you that you have a certain sugar intolerance, consult with him before taking this medication.
Galvus contains sodium
This medication contains less than 1mmol of sodium (23mg) per tablet; this is, essentially “sodium-free”.
Follow exactly the administration instructions for this medication as indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.
What amount to take and when
The Galvus dose that you should take varies depending on your condition. Your doctor will indicate exactly the number of Galvus tablets you should take. The maximum daily dose is 100 mg.
The recommended dose of Galvus is:
How to take Galvus
Duration of Galvus treatment
If you take more Galvus than you should
If you have taken too many Galvus tablets, or if someone else has taken your medication, consult your doctor immediately. You may need medical attention. If you need to visit a doctor or go to the nearest hospital, bring the packaging with you.
If you forget to take Galvus
If you forget to take a dose of this medication, take it as soon as you remember. Then take the next dose at your usual time. If it is almost time for your next dose, skip the missed dose. Do not take a double dose to make up for the missed doses.
If you interrupt Galvus treatment
Do not stop taking Galvus unless your doctor tells you to. If you have doubts about the duration of Galvus treatment, consult your doctor.
Like all medicines, this medicine may cause side effects, although not everyone will experience them.
Some symptoms require immediate medical attention
You should stop taking Galvus and seek medical attention immediately if you experience any of the following side effects:
Other side effects
Some patients experienced the following side effects while taking Galvus:
Since the marketing of this product, the following side effects have also been reported:
Reporting side effects
If you experience any type of side effect, consult your doctor, pharmacist, or nurse, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the national notification system included in theAppendix V. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Each tablet contains 50 mg of vildagliptin.
Appearance of the product and contents of the package
Galvus 50 mg tablets are round, white to light yellow, flat tablets with "NVR" on one face and "FB" on the other.
Galvus 50 mg tablets are available in packages containing 7, 14, 28, 30, 56, 60, 90, 112, 180, or 336 tablets and in multiple pack formats consisting of 3 packages, each containing 112 tablets.
Only some package sizes may be marketed.
Marketing Authorization Holder
Novartis Europharm Limited
Vista Building
Elm Park, Merrion Road
Dublin 4
Ireland
Responsible for manufacturing
Lek d.d.
Verovskova ulica 57
Ljubljana 1526
Slovenia
Novartis Farmacéutica S.A.
Gran Via de les Corts Catalanes, 764
08013 Barcelona
Spain
Novartis Pharma GmbH
Roonstraße 25
D-90429 Nuremberg
Germany
Novartis Pharmaceutical Manufacturing LLC
Verovskova ulica 57
Ljubljana 1000
Slovenia
Novartis Pharma GmbH
Sophie-Germain-Strasse 10
90443 Nürnberg
Germany
For more information about this medication, please contact the local representative of the marketing authorization holder:
Belgium/Belgique/Belgien Novartis Pharma N.V. Tel: +32 2 246 16 11 | Lithuania SIA Novartis Baltics Lietuvos filialas Tel: +370 5 269 16 50 |
Bulgaria Novartis Bulgaria EOOD Tel: +359 2 489 98 28 | Luxembourg/Luxemburg Novartis Pharma N.V. Tel: +32 2 246 16 11 |
Czech Republic Novartis s.r.o. Tel: +420 225 775 111 | Hungary Novartis Hungária Kft. Tel.: +36 1 457 65 00 |
Denmark Novartis Healthcare A/S Tlf: +45 39 16 84 00 | Malta Novartis Pharma Services Inc. Tel: +356 2122 2872 |
Germany Novartis Pharma GmbH Tel: +49 911 273 0 | Netherlands Novartis Pharma B.V. Tel: +31 88 04 52 111 |
Estonia SIA Novartis Baltics Eesti filiaal Tel: +372 66 30 810 | Norway Novartis Norge AS Tlf: +47 23 05 20 00 |
Greece Novartis (Hellas) A.E.B.E. Tel: +30 210 281 17 12 | Austria Novartis Pharma GmbH Tel: +43 1 86 6570 |
Spain Novartis Farmacéutica, S.A. Tel: +34 93 306 42 00 | Poland Novartis Poland Sp. z o.o. Tel.: +48 22 375 4888 |
France Novartis Pharma S.A.S. Tel: +33 1 55 47 66 00 | Portugal Novartis Farma - Produtos Farmacêuticos, S.A. Tel: +351 21 000 8600 |
Croatia Novartis Hrvatska d.o.o. Tel. +385 1 6274 220 | Romania Novartis Pharma Services Romania SRL Tel: +40 21 31299 01 |
Ireland Novartis Ireland Limited Tel: +353 1 260 12 55 | Slovenia Novartis Pharma Services Inc. Tel: +386 1 300 75 50 |
Iceland Vistor hf. Tel: +354 535 7000 | Slovakia Novartis Slovakia s.r.o. Tel: +421 2 5542 5439 |
Italy Novartis Farma S.p.A. Tel: +39 02 96 54 1 | Finland Novartis Finland Oy Tel: +358 (0)10 6133 200 |
Cyprus Novartis Pharma Services Inc. Tel: +357 22 690 690 | Sweden Novartis Sverige AB Tel: +46 8 732 32 00 |
Lithuania SIA Novartis Baltics Tel: +371 67 887 070 |
Last reviewed date of this leaflet:
Other sources of information
The detailed information on this medication is available on the European Medicines Agency website: http://www.ema.europa.eu
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.